Canopy Growth's Business Is Improving. So Why Isn't the Stock Performing Better?
Key Points
Canopy Growth recently reported incrementally stronger results, but the stock continues to languish.
Slow legalization progress and share dilution keeps weighing on its performance.
Until these issues are resolved, stick to stronger plays, such as profitable multi-state operators.
- 10 stocks we like better than Canopy Growth ›
As seen in Canopy Growth's (NASDAQ: CGC) latest quarterly earnings release, a turnaround remains in motion. In its fiscal 2027's first quarter, ended June 30, 2026, the Canada-based cannabis company reported net revenue of $81.2 million CAD ($58.6 million), a 13% increase compared to the prior year's quarter. More importantly, the company reported higher gross margins, a 68% decrease in net losses, and 59% drop in adjusted EBITDA losses.
While not yet a perfect situation, things are clearly improving. So then, why is this marijuana stock still languishing under $1 per share? Chalk it up to two lingering issues, headwinds that have also contributed to the stock's 33% drop over the past 12 months.
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Image source: Getty Images.
Still waiting on U.S. legalization progress
Earlier in 2026, it seemed as though this would be the year that legalization progress finally took shape on the federal level. Back in April, the U.S. Department of Justice and Drug Enforcement Administration rescheduled medical marijuana from Schedule I to Schedule III.
However, this wasn't the "game changer" speculators treated it as, as suggested by the short-lived rally among marijuana stocks during this time. So far, there's been little movement in getting recreational marijuana rescheduled. Although it would take further reforms to enable Canopy to start exporting its marijuana to the U.S., progress with rescheduling state-licensed recreational marijuana would at least bode well for Canopy's U.S. affiliate, Canopy USA.
Don't forget the dilution problem
Canopy Growth's second big issue is its continued reliance on newly raised outside equity capital. Over the past year, Canopy's share count has increased from 239.9 million to 423 million.
Most of this came from at-the-market (ATM) equity program sales of newly issued stock in mid-2025. A separate ATM program, authorized in August 2025, gives it the right to raise another $200 million. Given the stock's current market cap of $394 million, the company could severely dilute shareholders yet again.
As these two issues persist, keep skipping on Canopy Growth. Stick with stronger cannabis stocks, such as shares in profitable cannabis companies with minimal dilution risk, instead.
Should you buy stock in Canopy Growth right now?
Before you buy stock in Canopy Growth, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Canopy Growth wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $417,413!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,341,294!*
Now, it’s worth noting Stock Advisor’s total average return is 950% — a market-crushing outperformance compared to 212% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of September 14, 2026.
Thomas Niel has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
